Literature DB >> 24627131

NRP-1 expression in bladder cancer and its implications for tumor progression.

Wen Cheng1, Dian Fu, Zhi-Feng Wei, Feng Xu, Xiao-Feng Xu, You-Huang Liu, Jing-Ping Ge, Feng Tian, Cong-Hui Han, Zheng-Yu Zhang, Li-Ming Zhou.   

Abstract

Neuropilin-1 (NRP-1) overexpression has been reported in a variety of human cancers. However, the role of NRP-1 in bladder cancer (BC) remains unclear. The aim of present study was to analyze NRP-1 protein expression in BC tissues and to assess its prognostic significance for BC. NRP-1 messenger ribonucleic acid (mRNA) and protein expression were determined by real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and immunohistochemistry in specimens of primary cancer and their adjacent noncancerous tissues in BC patients. Additionally, NRP-1 protein expression in 139 archived paraffin-embedded BC samples was analyzed by immunohistochemistry and correlated with clinicopathological characteristics and survival. Student's t test, Spearman's rank correlation, Kaplan-Meier plots, and Cox's proportional hazards regression model were used to analyze the data. By qRT-PCR and immunohistochemistry, the levels of NRP-1 mRNA and protein were significantly higher in BC, compared to that in adjacent noncancerous tissues (P<0.001). High expression of NRP-1 was significantly associated with histologic grade (P=0.016) and tumor stage (P=0.001). Multivariate analysis showed that high expression of NRP-1 was an independent prognostic factor for overall survival. Our study suggests that overexpression of NRP-1 may play an important role in the progression of BC, and NRP-1 expression may serve as a biomarker for poor prognosis for BC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24627131     DOI: 10.1007/s13277-014-1806-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression.

Authors:  H Q Miao; P Lee; H Lin; S Soker; M Klagsbrun
Journal:  FASEB J       Date:  2000-12       Impact factor: 5.191

2.  Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line.

Authors:  Christin Tse; Ruinua H Xiang; Todd Bracht; Susan L Naylor
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

3.  Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B.

Authors:  Y Tomizawa; Y Sekido; M Kondo; B Gao; J Yokota; J Roche; H Drabkin; M I Lerman; A F Gazdar; J D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

4.  Expression and regulation of neuropilin-1 in human astrocytomas.

Authors:  H Ding; X Wu; L Roncari; N Lau; P Shannon; A Nagy; A Guha
Journal:  Int J Cancer       Date:  2000-11-15       Impact factor: 7.396

Review 5.  Urothelial cancer biomarkers for detection and surveillance.

Authors:  Louis S Liou
Journal:  Urology       Date:  2006-03       Impact factor: 2.649

6.  Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract.

Authors:  Donna E Hansel; Robert E Wilentz; Charles J Yeo; Richard D Schulick; Elizabeth Montgomery; Anirban Maitra
Journal:  Am J Surg Pathol       Date:  2004-03       Impact factor: 6.394

7.  Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma.

Authors:  Alexander A Parikh; Wen Biao Liu; Fan Fan; Oliver Stoeltzing; Niels Reinmuth; Christiane J Bruns; Corazon D Bucana; Douglas B Evans; Lee M Ellis
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

8.  Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect.

Authors:  Emely Castro-Rivera; Sophia Ran; Philip Thorpe; John D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-23       Impact factor: 11.205

9.  A requirement for neuropilin-1 in embryonic vessel formation.

Authors:  T Kawasaki; T Kitsukawa; Y Bekku; Y Matsuda; M Sanbo; T Yagi; H Fujisawa
Journal:  Development       Date:  1999-11       Impact factor: 6.868

10.  Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs.

Authors:  T Kitsukawa; A Shimono; A Kawakami; H Kondoh; H Fujisawa
Journal:  Development       Date:  1995-12       Impact factor: 6.868

View more
  14 in total

1.  Neuropilin 1 Receptor Is Up-Regulated in Dysplastic Epithelium and Oral Squamous Cell Carcinoma.

Authors:  Shokoufeh Shahrabi-Farahani; Marina Gallottini; Fabiana Martins; Erik Li; Dayna R Mudge; Hironao Nakayama; Kyoko Hida; Dipak Panigrahy; Patricia A D'Amore; Diane R Bielenberg
Journal:  Am J Pathol       Date:  2016-02-11       Impact factor: 4.307

2.  Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.

Authors:  Celine Kerros; Satyendra C Tripathi; Dongxing Zha; Jennifer M Mehrens; Anna Sergeeva; Anne V Philips; Na Qiao; Haley L Peters; Hiroyuki Katayama; Pariya Sukhumalchandra; Kathryn E Ruisaard; Alexander A Perakis; Lisa S St John; Sijie Lu; Elizabeth A Mittendorf; Karen Clise-Dwyer; Amanda C Herrmann; Gheath Alatrash; Carlo Toniatti; Samir M Hanash; Qing Ma; Jeffrey J Molldrem
Journal:  J Biol Chem       Date:  2017-05-03       Impact factor: 5.157

3.  High Expression of Neuropilin-1 Associates with Unfavorable Clinicopathological Features in Hepatocellular Carcinoma.

Authors:  Yafei Zhang; Peng Liu; Yizhen Jiang; Xiaofeng Dou; Jianghua Yan; Chao Ma; Qun Fan; Weixing Wang; Fu Su; Hui Tang; Xinhui Su
Journal:  Pathol Oncol Res       Date:  2015-11-13       Impact factor: 3.201

4.  Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.

Authors:  Ahva Shahabi; Juan Pablo Lewinger; Jie Ren; Craig April; Andy E Sherrod; Joseph G Hacia; Siamak Daneshmand; Inderbir Gill; Jacek K Pinski; Jian-Bing Fan; Mariana C Stern
Journal:  Prostate       Date:  2016-06-08       Impact factor: 4.012

5.  Peritumoral Neuropilin-1 and VEGF receptor-2 expression increases time to recurrence in hepatocellular carcinoma patients undergoing curative hepatectomy.

Authors:  Peng-Yuan Zhuang; Jian-Dong Wang; Zhao-Hui Tang; Xue-Ping Zhou; Yong Yang; Zhi-Wei Quan; Ying-Bin Liu; Jun Shen
Journal:  Oncotarget       Date:  2014-11-30

6.  Circulating soluble neuropilin-1 in patients with early cervical cancer and cervical intraepithelial neoplasia can be used as a valuable diagnostic biomarker.

Authors:  Shouhua Yang; Henghui Cheng; Zaiju Huang; Xiaoling Wang; Yinglu Wan; Jing Cai; Zehua Wang
Journal:  Dis Markers       Date:  2015-03-19       Impact factor: 3.434

Review 7.  Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

Authors:  Rita Azevedo; Andreia Peixoto; Cristiana Gaiteiro; Elisabete Fernandes; Manuel Neves; Luís Lima; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  Oncotarget       Date:  2017-07-21

Review 8.  SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia.

Authors:  Elisabetta Valentini; Marta Di Martile; Donatella Del Bufalo; Simona D'Aguanno
Journal:  J Exp Clin Cancer Res       Date:  2021-04-15

9.  Role of NRP1 in Bladder Cancer Pathogenesis and Progression.

Authors:  Yang Dong; Wei-Ming Ma; Zhen-Duo Shi; Zhi-Guo Zhang; Jia-He Zhou; Yang Li; Shao-Qi Zhang; Kun Pang; Bi-Bo Li; Wen-da Zhang; Tao Fan; Guang-Yuan Zhu; Liang Xue; Rui Li; Ying Liu; Lin Hao; Cong-Hui Han
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

10.  Neuropilin-1 is up-regulated by cancer-associated fibroblast-secreted IL-8 and associated with cell proliferation of gallbladder cancer.

Authors:  Chen Chen; Rui Zhang; Li Ma; Qi Li; Ya-Ling Zhao; Guan-Jun Zhang; Dong Zhang; Wen-Zhi Li; Sheng Cao; Lin Wang; Zhi-Min Geng
Journal:  J Cell Mol Med       Date:  2020-09-20       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.